Form 4: 4D Molecular Therapeutics CLO Sells Shares

4D Molecular Therapeutics' Chief Legal Officer, Scott Bizily, executed a pre-planned sale of 1,635 common shares following the exercise of stock options.

Summary

• Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, Inc. (FDMT), engaged in a pre-planned transaction on December 16, 2025.
• The transaction involved the exercise of stock options to acquire 1,635 shares of common stock at an exercise price of $4.14 per share.
• Immediately following the exercise, 1,635 shares of common stock were sold at a price of $10.90 per share.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on June 6, 2025.
• Following these transactions, Scott Bizily directly owns 3,594 shares of common stock and holds options for 73,595 derivative securities.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine exercise of options and subsequent sale under a pre-arranged 10b5-1 plan, which typically does not signal strong positive or negative sentiment about the company's future prospects. The officer realized a profit, which is positive for the individual, but the reduction in direct share ownership is a minor negative from an investor's perspective, balanced by the pre-planned nature.

Positives

• The officer realized a profit from exercising options at $4.14 and selling shares at $10.90, indicating a positive return on vested options.
• The transaction was pre-planned under a Rule 10b5-1 trading plan, suggesting it was not based on new, non-public information.

Negatives

• The Chief Legal Officer reduced their direct beneficial ownership of common stock by 1,635 shares, from an implied 5,229 shares to 3,594 shares.

Future Outlook

NA

Management Comments

• Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.
• The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Industry Context

This is an insider transaction report, which is common across all industries for publicly traded companies. It does not provide specific industry context beyond the company's sector (biotechnology, implied by name).

Stakeholder Impact

• Shareholders: The sale by a Chief Legal Officer, even if pre-planned, could be perceived as a slight negative, but the routine nature under a 10b5-1 plan mitigates concerns.
• Employees: The vesting schedule for options is a standard compensation mechanism, impacting the reporting person's long-term incentives.

Next Steps

• Continued vesting of 73,595 stock options for Scott Bizily, with 1/48th vesting monthly from March 6, 2025, until fully vested on March 6, 2029.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction (option exercise and sale) by the Chief Legal Officer. Such transactions, especially when executed under a Rule 10b5-1 plan, are generally not considered strong indicators of future company performance or management's sentiment. The officer realized a profit, which is positive for the individual, but the reduction in direct share ownership is minor and offset by the pre-planned nature. Therefore, this filing alone does not provide sufficient new information to warrant a change in investment recommendation; a 'hold' stance is appropriate, pending more substantive company news or financial results.

Keywords

4D Molecular Therapeutics, FDMT, Scott Bizily, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Rule 10b5-1, Chief Legal Officer, Biotechnology